Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancerNicole F. Bonan(American University), Kathleen DeCicco-Skinner(American University)OncogenesisJanuary 2, 201910.1038/s41389-018-0109-8Cited by 33SaveCiteExport RISWatch citationsRelated PapersUnlocking Drug Resistance in Multiple Myeloma: Adipocytes as Modulators of Treatment Response|Cancers|2023|8Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes|PLoS ONE|2022|1Increased EGFR/HER2 Pathway Activation Contributes to Skin Tumorigenesis in Tpl2−/− Mice|Cancers|2025|0